Dawson Neil, McDonald Martin, Higham Desmond J, Morris Brian J, Pratt Judith A
1] Psychiatric Research Institute of Neuroscience in Glasgow (PsyRING), Glasgow, UK [2] Centre for Neuroscience, University of Strathclyde (CeNsUS), Glasgow, UK [3] Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK.
1] Centre for Neuroscience, University of Strathclyde (CeNsUS), Glasgow, UK [2] Department of Bioengineering, University of Strathclyde, Glasgow, UK.
Neuropsychopharmacology. 2014 Jun;39(7):1786-98. doi: 10.1038/npp.2014.26. Epub 2014 Feb 4.
Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) receptor antagonist, is widely utilized as a translational model for schizophrenia. However, how acute NMDA receptor blockade impacts on brain functioning at a systems level, to elicit translationally relevant symptomatology and behavioral deficits, has not yet been determined. Here, for the first time, we apply established and recently validated topological measures from network science to brain imaging data gained from ketamine-treated mice to elucidate how acute NMDA receptor blockade impacts on the properties of functional brain networks. We show that the effects of acute ketamine treatment on the global properties of these networks are divergent from those widely reported in schizophrenia. Where acute NMDA receptor blockade promotes hyperconnectivity in functional brain networks, pronounced dysconnectivity is found in schizophrenia. We also show that acute ketamine treatment increases the connectivity and importance of prefrontal and thalamic brain regions in brain networks, a finding also divergent to alterations seen in schizophrenia. In addition, we characterize how ketamine impacts on bipartite functional interactions between neural subsystems. A key feature includes the enhancement of prefrontal cortex (PFC)-neuromodulatory subsystem connectivity in ketamine-treated animals, a finding consistent with the known effects of ketamine on PFC neurotransmitter levels. Overall, our data suggest that, at a systems level, acute ketamine-induced alterations in brain network connectivity do not parallel those seen in chronic schizophrenia. Hence, the mechanisms through which acute ketamine treatment induces translationally relevant symptomatology may differ from those in chronic schizophrenia. Future effort should therefore be dedicated to resolve the conflicting observations between this putative translational model and schizophrenia.
亚麻醉剂量的氯胺酮是一种非竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,其急性治疗被广泛用作精神分裂症的转化模型。然而,急性NMDA受体阻断在系统水平上如何影响大脑功能,以引发与转化相关的症状学和行为缺陷,尚未确定。在此,我们首次将网络科学中已确立且最近经过验证的拓扑测量方法应用于氯胺酮处理小鼠的脑成像数据,以阐明急性NMDA受体阻断如何影响功能性脑网络的特性。我们发现,急性氯胺酮治疗对这些网络全局特性的影响与精神分裂症中广泛报道的不同。急性NMDA受体阻断促进功能性脑网络的超连接性,而在精神分裂症中则发现明显的连接障碍。我们还表明,急性氯胺酮治疗增加了脑网络中前额叶和丘脑脑区的连接性和重要性,这一发现也与精神分裂症中观察到的改变不同。此外,我们描述了氯胺酮如何影响神经子系统之间的二分功能相互作用。一个关键特征是氯胺酮处理动物中前额叶皮质(PFC)-神经调节子系统连接性增强,这一发现与氯胺酮对PFC神经递质水平的已知影响一致。总体而言,我们的数据表明,在系统水平上,急性氯胺酮诱导的脑网络连接性改变与慢性精神分裂症中观察到的不同。因此,急性氯胺酮治疗诱导与转化相关症状学的机制可能与慢性精神分裂症中的机制不同。未来应致力于解决这个假定的转化模型与精神分裂症之间相互矛盾的观察结果。